CDK9 and acute myeloid leukemia: These findings were further corroborated by Cidado et al., who showed that the selective CDK9-inhibitor AZD4573 induced a rapid downregulation of Mcl-1 mRNA, followed by a downregulation of Mcl-1 on protein level within 4 h, which preceded the onset of subsequent caspase-activation in the AML cell line MV-4-11 [51].